Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 3/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7197775 | 0.98 | CYP4F2 (0.41) | CYP4F2CYP4A11SPHK1EPHX1CETP | |
| SCHEMBL5031163 | 0.98 | CYP4F2 (0.41) | CYP4F2CYP4A11SPHK1EPHX1CETP | |
| SCHEMBL1044919 | 0.98 | CYP4F2 (0.41) | CYP4F2CYP4A11SPHK1EPHX1CETP | |
| SCHEMBL12273347 | 0.93 | CETP (0.36) | CYP4F2CYP4A11SPHK1EPHX1CETP | |
| Hexane SCHEMBL6916261 | 0.90 | SOAT1 (0.44) | SPHK1CES2CES1MEN1KMT2A | |
| SCHEMBL5038262 | 0.90 | CETP (0.43) | CYP4F2CYP4A11SPHK1EPHX1CETP | |
| SCHEMBL5027335 | 0.90 | CYP4F2 (0.46) | CYP4F2CYP4A11SPHK1EPHX1CETP | |
| SCHEMBL3738398 | 0.88 | CETP (0.48) | CYP4F2CYP4A11SPHK1EPHX1CETP | |
| SCHEMBL2386979 | 0.88 | CETP (0.48) | CYP4F2CYP4A11SPHK1EPHX1CETP | |
| SCHEMBL10823975 | 0.88 | CETP (0.48) | CYP4F2CYP4A11SPHK1EPHX1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7070026-A | — | — | None | — | — | JP | disclosed |
| EP-1951708-B1 | PIPERAZINE DERIVATIVE USEFUL AS A CCR5 ANTAGONIST | MERCK SHARP & DOHME (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2342180-A2 | ORGANIC COMPOUNDS SUITABLE FOR MODULATING FRAGRANCE COMPOSITIONS | Givaudan SA (CH) | 2011-07-13 | — | — | EP | disclosed |
| EP-1632479-B1 | Pharmaceutical compositions comprising CCR5 antagonizing piperazine derivatives | SCHERING CORP (US) | 2011-01-12 | — | — | EP | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| WO-2010037244-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-04-08 | — | — | WO | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| EP-1951708-A2 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2008-08-06 | — | — | EP | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060105964-A1 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| EP-1632479-A2 | Piperazine derivatives useful as ccr5 antagonists | SCHERING CORPORATION (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1175401-B1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORP (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040067961-A1 | Piperazine derivatives useful as CCR5 antagonists | MERCK SHARP & DOHME CORP. | 2004-04-08 | — | — | US | disclosed |
| US-6689765-B2 | VIRICIDES; ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION | 2004-02-10 | — | — | US | disclosed |
| US-20030069252-A1 | Piperazine derivatives useful as CCR5 antagonists | MERCK SHARP & DOHME CORP. | 2003-04-10 | — | — | US | disclosed |
| US-6391865-B1 | AIDS THERAPY; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; SKIN DISORDERS | SCHERING CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-1175401-A1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066558-A1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| JP-H0770026-A | PRODUCTION OF CARBAMOYLACYLCYCLOPROPANE COMPOUND AND 2-CARBAMOYLACYL-4-BUTANOLIDE COMPOUND TO BE USED THEREFOR | FUJI PHOTO FILM CO LTD | 1995-03-14 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR2 | CYP4F2 3492/4885CYP4A11 1369/4885SPHK1 275/4885 |
| US-20030069252-A1 | Piperazine derivatives useful as CCR5 antagonists | CCR5, CCR2, CXCR3 | CYP4F2 2453/4885CYP4A11 787/4885SPHK1 272/4885 |
| US-20040067961-A1 | Piperazine derivatives useful as CCR5 antagonists | CCR5, CCR2, CXCR3 | CYP4F2 2453/4885CYP4A11 787/4885SPHK1 272/4885 |
| US-20060105964-A1 | Piperazine derivatives useful as CCR5 antagonists | CCR5, CCR2, CXCR3 | CYP4F2 2454/4885CYP4A11 790/4885SPHK1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.